IS2708B - Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar - Google Patents

Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar

Info

Publication number
IS2708B
IS2708B IS8071A IS8071A IS2708B IS 2708 B IS2708 B IS 2708B IS 8071 A IS8071 A IS 8071A IS 8071 A IS8071 A IS 8071A IS 2708 B IS2708 B IS 2708B
Authority
IS
Iceland
Prior art keywords
pharmaceutical formulations
related conditions
treating atherosclerosis
dysplasia
lipid
Prior art date
Application number
IS8071A
Other languages
English (en)
Other versions
IS8071A (is
Inventor
Kang Cheng
M Gerard Waters
Kathleen M Metters
Gary O'neill
Original Assignee
Merck Sharp & Dohme
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2708(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Merck Frosst Canada Ltd filed Critical Merck Sharp & Dohme
Publication of IS8071A publication Critical patent/IS8071A/is
Publication of IS2708B publication Critical patent/IS2708B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IS8071A 2003-05-15 2005-10-13 Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar IS2708B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15
PCT/US2004/014980 WO2004103370A1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
IS8071A IS8071A (is) 2005-10-13
IS2708B true IS2708B (is) 2011-01-15

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8071A IS2708B (is) 2003-05-15 2005-10-13 Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar

Country Status (45)

Country Link
US (4) US20040229844A1 (is)
EP (3) EP2116244B1 (is)
JP (2) JP4637833B2 (is)
KR (2) KR100806008B1 (is)
CN (3) CN102526735A (is)
AR (1) AR041089A1 (is)
AU (2) AU2004240597B2 (is)
BR (1) BRPI0410273A (is)
CA (1) CA2525772C (is)
CL (1) CL2004001056A1 (is)
CO (1) CO5630034A2 (is)
CR (2) CR8047A (is)
CY (2) CY1109476T1 (is)
DE (1) DE602004022036D1 (is)
DK (2) DK1624871T3 (is)
DO (1) DOP2004000907A (is)
EA (2) EA011895B1 (is)
EC (1) ECSP056156A (is)
ES (2) ES2392743T3 (is)
GE (2) GEP20105025B (is)
GT (1) GT200400098A (is)
HK (1) HK1092722A1 (is)
HN (1) HN2004000171A (is)
HR (2) HRP20090424T1 (is)
IL (1) IL171962A (is)
IS (1) IS2708B (is)
JO (1) JO2564B1 (is)
MA (1) MA27835A1 (is)
ME (1) MEP60108A (is)
MX (1) MXPA05012272A (is)
MY (1) MY140639A (is)
NO (1) NO20055957L (is)
NZ (2) NZ572515A (is)
PA (1) PA8603201A1 (is)
PE (1) PE20050552A1 (is)
PL (2) PL1624871T3 (is)
PT (2) PT1624871E (is)
RS (3) RS20120498A1 (is)
SG (1) SG153667A1 (is)
SI (2) SI2116244T1 (is)
TN (1) TNSN05290A1 (is)
TW (2) TWI341199B (is)
UA (1) UA89615C2 (is)
WO (1) WO2004103370A1 (is)
ZA (1) ZA200508288B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447779C (en) * 2001-05-23 2010-08-31 Zhaoyin Wang Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
HUE031950T2 (en) 2004-10-08 2017-08-28 Forward Pharma As Controlled release pharmaceutical compositions containing fumaric acid ester
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
CA2598273A1 (en) * 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008538277A (ja) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 脂質関連障害の治療用の組成物および方法
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1885726B1 (en) * 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2007027532A2 (en) * 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
RU2008112313A (ru) * 2005-09-01 2009-10-10 Эррэй Биофарма Инк. (Us) Соединения ингибиторы raf и способы их применения
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
BRPI0620255A2 (pt) * 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
CN101400682A (zh) * 2006-01-20 2009-04-01 先灵公司 治疗异常脂血症的杂环烟酸受体激动剂
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
MX2009002918A (es) * 2006-09-15 2009-03-31 Schering Corp Derivados azetidinona y sus metodos de uso.
MX2009002924A (es) * 2006-09-15 2009-05-28 Schering Corp Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2114154B1 (en) * 2007-02-08 2013-08-28 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
US20100015220A1 (en) * 2008-05-20 2010-01-21 Wetterau John R Niacin and nsaid combination therapy
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2341773A4 (en) * 2008-09-24 2012-03-07 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
PT2564839T (pt) 2009-01-09 2016-07-14 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
TW201200133A (en) 2010-03-16 2012-01-01 Aventis Pharma Inc Substituted pyrimidines as prostaglandin D2 receptor antagonists
CA2793324A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2857653A1 (de) 1977-09-30 1981-02-05 Rca Corp Einrichtung in einem fernsehsystem
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0821587A4 (en) * 1995-04-19 1999-05-19 Lipoprotein Technologies Inc COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION
DE69621952T2 (de) 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
AU725622B2 (en) 1995-12-22 2000-10-19 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
JP4870869B2 (ja) * 1997-07-31 2012-02-08 コス・ライフ・サイエンシズ・インコーポレイテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤とニコチン酸化合物との組み合わせ、及び夜に１日１回高脂質血症を治療する方法
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
HUP0101110A3 (en) * 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ES2244238T3 (es) 1998-12-07 2005-12-01 Schering Corporation Proceso para la sintesis de azetidinonas.
CN1342091A (zh) 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
AU3382699A (en) 1999-04-05 2000-10-23 Schering Corporation Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
US20040254224A1 (en) 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
CA2447779C (en) * 2001-05-23 2010-08-31 Zhaoyin Wang Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
EP1424335A4 (en) 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
BR0308518A (pt) 2002-03-19 2005-02-22 Ono Pharmaceutical Co Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo
DE60326232D1 (de) * 2002-06-03 2009-04-02 Novartis Ag Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
KR20060012617A (ko) 2006-02-08
HRP20120818T1 (hr) 2012-11-30
CN101559227B (zh) 2012-03-21
PA8603201A1 (es) 2005-02-04
ES2392743T3 (es) 2012-12-13
IL171962A (en) 2012-06-28
NO20055957L (no) 2006-02-14
MY140639A (en) 2010-01-15
TNSN05290A1 (en) 2007-07-10
CY1113342T1 (el) 2016-06-22
AU2004240597A1 (en) 2004-12-02
CO5630034A2 (es) 2006-04-28
ZA200508288B (en) 2008-08-27
SI2116244T1 (sl) 2012-12-31
UA89615C2 (ru) 2010-02-25
JP2010077151A (ja) 2010-04-08
MA27835A1 (fr) 2006-04-03
SI1624871T1 (sl) 2009-12-31
JP2006526030A (ja) 2006-11-16
PL1624871T3 (pl) 2009-12-31
AU2011200986B2 (en) 2012-11-08
PL2116244T3 (pl) 2013-01-31
NZ543399A (en) 2009-02-28
CA2525772C (en) 2011-03-15
EP2286816A1 (en) 2011-02-23
RS52731B (sr) 2013-08-30
EP1624871A1 (en) 2006-02-15
CL2004001056A1 (es) 2005-03-28
JP4637833B2 (ja) 2011-02-23
PE20050552A1 (es) 2005-08-06
RS20120498A1 (en) 2013-08-30
CY1109476T1 (el) 2014-08-13
JO2564B1 (en) 2010-11-03
BRPI0410273A (pt) 2006-05-16
ECSP056156A (es) 2006-04-19
DK2116244T3 (da) 2012-11-26
TW200803844A (en) 2008-01-16
EA011895B1 (ru) 2009-06-30
AR041089A1 (es) 2005-05-04
MXPA05012272A (es) 2006-05-19
IS8071A (is) 2005-10-13
EP2116244B1 (en) 2012-08-08
EA200501817A1 (ru) 2006-06-30
CN102526735A (zh) 2012-07-04
GEP20084569B (en) 2008-12-25
HK1092722A1 (en) 2007-02-16
CN100441184C (zh) 2008-12-10
DK1624871T3 (da) 2009-11-16
US20100076002A1 (en) 2010-03-25
RS20120499A1 (en) 2013-08-30
DOP2004000907A (es) 2004-11-30
CN101559227A (zh) 2009-10-21
GT200400098A (es) 2005-03-03
PT1624871E (pt) 2009-09-07
ES2328148T3 (es) 2009-11-10
EA200702674A1 (ru) 2008-04-28
WO2004103370A1 (en) 2004-12-02
US20090233977A1 (en) 2009-09-17
EP1624871B1 (en) 2009-07-15
HRP20090424T1 (en) 2009-09-30
KR100960749B1 (ko) 2010-06-01
IL171962A0 (en) 2006-04-10
CR8047A (es) 2006-07-14
TWI334354B (en) 2010-12-11
CR9808A (es) 2008-07-29
US20040229844A1 (en) 2004-11-18
DE602004022036D1 (de) 2009-08-27
RS20050777A (sr) 2008-04-04
CA2525772A1 (en) 2004-12-02
AU2004240597B2 (en) 2011-01-06
EP2116244A1 (en) 2009-11-11
TW200503757A (en) 2005-02-01
KR20080003470A (ko) 2008-01-07
SG153667A1 (en) 2009-07-29
GEP20105025B (en) 2010-06-25
TWI341199B (en) 2011-05-01
US20110118292A1 (en) 2011-05-19
CN1787819A (zh) 2006-06-14
HN2004000171A (es) 2011-07-11
EA009744B1 (ru) 2008-04-28
KR100806008B1 (ko) 2008-02-26
PT2116244E (pt) 2012-11-02
NZ572515A (en) 2010-07-30
AU2011200986A1 (en) 2011-03-31
MEP60108A (en) 2011-05-10

Similar Documents

Publication Publication Date Title
IS2708B (is) Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
IS2878B (is) Arípíprazól-samsett lyfjaform og aðferð
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DK1530972T3 (da) Fremgangsmåde til screening for parasitpræparaters effektivitet i forebyggelse og kontrol af sygdomme
NO20034218D0 (no) Fremgangsmåte og anordning til avkutting av undervannsstrukturer
DK1489931T3 (da) Elektrisk rygesystem og fremgangsmåde
DK1415535T4 (da) Sprøjtesystem og fremgangsmåde til et sådant
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
IS8484A (is) Kerfi og aðferð til að dyfta og úrhluta raka
NO20055778D0 (no) Folgesystem og assosiert fremgangsmate
NO20051875D0 (no) Kjoleror og fremgangsmate for bruk av dette
NO20053874L (no) Formulering og metoder for behandling av thrombocytemi
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20055759D0 (no) Fremgangsmate og system for nedihullsklokke
DK1786680T3 (da) Beskyttet hætteglas og fremgangsmåde til fremstilling heraf
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
NO20052188D0 (no) System og fremgangsmate for fremstilling av polysulfid
NO20030843D0 (no) Anordning og fremgangsmåte for kultivering
NO20030438D0 (no) Fremgangsmåte og anordning for stöping av betongprodukter
DK1819320T3 (da) Oralt dispergerbar farmaceutisk sammensætning og fremgangsmåde til fremstilling heraf
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
DK1540249T3 (da) System og fremgangsmåde til at blæse løsfyldsisolering
DK1691621T3 (da) Mælkeprodukt og fremgangsmåde